2017 ACVIM Forum Research Abstract Program

PAC-1 shows therapeutic promise in the treatment of canine intracranial neoplasia, as well as high grade human astrocytoma. Investigation of therapeutic approaches that combine PAC-1 with radiation therapy and/or temozolomide will further elucidate its therapeutic potential in murine models and canine patients. Canine B-cell lymphoma is a common hematologic malignancy and a clinically heterogeneous disease. Little progress has been made to improve remission duration and survival. The primary goal of this study was to correlate modified WHO histopathologic subclassification and flow cytometry (FC) with clinical outcome. We hypothesized that histologically distinct subclassifications would have unique cell surface markers as determined by FC, and these subcategories of disease would have variable outcomes when treated with a standardized treatment protocol.